

Freedom of Information Act 2000 - Request Reference Fol/21/448
Biologic Drugs used in Gastroenterology

Request Details

I am analysing the usage of new biologic medications in gastroenterology. I would greatly appreciate if you could answer the following two questions.

1. How many patients were treated in August 2021 (or latest available month) by the gastroenterology department with the following drugs:

Adalimumab (any brand or biosimilar)	229
Infliximab (any brand or biosimilar)	2
Ustekinumab (Stelara)	0
Vedolizumab (Entyvio)	171
Tofacitinib (Xeljanz)	5
Filgotinib (Jyseleca)	0

2. How many patients were treated in August 2021 (or latest available month) for Crohn's Disease ONLY with the following drugs:
 - Adalimumab (any brand or biosimilar)
 - Infliximab (any brand or biosimilar)
 - Ustekinumab (Stelara)
 - Vedolizumab (Entyvio)

Cardiff and Vale University Health Board does not hold this data. Under our Section 16 obligation to provide advice and assistance, I can inform you that we are unable to identify prescriptions that are treatment specific.